ABEO
Price
$4.34
Change
-$0.06 (-1.36%)
Updated
Oct 26, 12:29 PM (EDT)
Capitalization
251.61M
16 days until earnings call
Intraday BUY SELL Signals
TSHA
Price
$4.08
Change
+$0.13 (+3.28%)
Updated
Oct 26, 11:21 AM (EDT)
Capitalization
1.29B
8 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABEO vs TSHA

ABEO vs TSHA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABEO vs. TSHA commentary
Oct 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a StrongBuy and TSHA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABEO with price predictions
Oct 23, 2026

ABEO's Stochastic Oscillator dives into oversold zone

The Stochastic Oscillator for ABEO moved into oversold territory on October 23, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABEO's RSI Oscillator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

Following a +2.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in 212 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ABEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ABEO turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 34 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

The 50-day moving average for ABEO moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for ABEO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.965) is normal, around the industry mean (3.035). P/E Ratio (-3.636) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (13.089) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ABEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TSHA with price predictions
Oct 23, 2026

TSHA sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for TSHA moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSHA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TSHA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TSHA's RSI Indicator exited the oversold zone, 32 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 66 cases where TSHA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for TSHA just turned positive on October 21, 2026. Looking at past instances where TSHA's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.

Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSHA advanced for three days, in 216 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

TSHA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.332) is normal, around the industry mean (3.035). P/E Ratio (-9.659) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. TSHA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TSHA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABEO vs TSHA: Fundamental Ratings
ABEO
TSHA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
7981
P/E GROWTH RATING
1..100
9817
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TSHA's Valuation (21) in the null industry is in the same range as ABEO (30) in the Pharmaceuticals Generic industry. This means that TSHA’s stock grew similarly to ABEO’s over the last 12 months.

TSHA's Profit vs Risk Rating (100) in the null industry is in the same range as ABEO (100) in the Pharmaceuticals Generic industry. This means that TSHA’s stock grew similarly to ABEO’s over the last 12 months.

TSHA's SMR Rating (98) in the null industry is in the same range as ABEO (98) in the Pharmaceuticals Generic industry. This means that TSHA’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's Price Growth Rating (79) in the Pharmaceuticals Generic industry is in the same range as TSHA (81) in the null industry. This means that ABEO’s stock grew similarly to TSHA’s over the last 12 months.

TSHA's P/E Growth Rating (17) in the null industry is significantly better than the same rating for ABEO (98) in the Pharmaceuticals Generic industry. This means that TSHA’s stock grew significantly faster than ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOTSHA
RSI
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
88%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 22 days ago
83%
Bullish Trend 6 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
COMPARISON
Comparison
Oct 26, 2026
Stock price -- (ABEO: $4.40 vs. TSHA: $3.96)
Brand notoriety: ABEO and TSHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 63% vs. TSHA: 77%
Market capitalization -- ABEO: $251.61M vs. TSHA: $1.29B
ABEO [@Biotechnology] is valued at $251.61M. TSHA’s [@Biotechnology] market capitalization is $1.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 1 FA rating(s) are green while TSHA’s FA Score has 2 green FA rating(s).

  • ABEO’s FA Score: 1 green, 4 red.
  • TSHA’s FA Score: 2 green, 3 red.
According to our system of comparison, TSHA is a better buy in the long-term than ABEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 4 TA indicator(s) are bullish while TSHA’s TA Score has 5 bullish TA indicator(s).

  • ABEO’s TA Score: 4 bullish, 4 bearish.
  • TSHA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, TSHA is a better buy in the short-term than ABEO.

Price Growth

ABEO (@Biotechnology) experienced а -0.68% price change this week, while TSHA (@Biotechnology) price change was +9.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.04%. For the same industry, the average monthly price growth was -12.59%, and the average quarterly price growth was -12.28%.

Reported Earning Dates

ABEO is expected to report earnings on Nov 11, 2026.

TSHA is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (+5.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABEO
Daily Signal:
Gain/Loss:
TSHA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

TSHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TSHA has been loosely correlated with MGTX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if TSHA jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSHA
1D Price
Change %
TSHA100%
-1.12%
MGTX - TSHA
52%
Loosely correlated
-5.73%
SLDB - TSHA
52%
Loosely correlated
-4.36%
STOK - TSHA
51%
Loosely correlated
-2.57%
ABEO - TSHA
51%
Loosely correlated
-1.57%
LXEO - TSHA
49%
Loosely correlated
-3.11%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TEAM227.614.45
+1.99%
Atlassian Corp
HDSN5.370.01
+0.19%
Hudson Technologies
KBR39.23-0.30
-0.76%
KBR
MCRB2.09-0.04
-1.88%
Seres Therapeutics Inc
DLX23.32-0.55
-2.30%
Deluxe Corp